Total Funding
86
58
Total FundingPost-IPO Debt raised
Growth Score
-8 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
21912
Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.
- Kelly Beck: Vice President, Investor Relations and OperationsPast Role: PRA Health Sciences, Director of Human Resources
Uday B. Kompella: Co-Founder
About the Company
Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and commercializing gene treatments to cure blinding illnesses, as well as developing a COVID-19 vaccine to save lives. The biologic product candidate aims to provide better therapy
to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy using the breakthrough modifier gene therapy platform.
